CEBPA and leukemia: In a subsequent study, Su et al. reported that R-2-hydroxyglutarate (R-2HG), originally thought to be an oncometabolite, strongly inhibited FTO activity, thereby increasing global m6A modifications, resulting in reduced mRNA stability of MYC/CEBPA in R-2HG-sensitive leukemia cells (Su et al., 2018).